Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Jun 11;15(1):540-544.
doi: 10.1515/med-2020-0136. eCollection 2020.

Thalidomide-induced serious RR interval prolongation (longest interval >5.0 s) in multiple myeloma patient with rectal cancer: A case report

Li Huang  1 , Yuemin Kuang  1 , Zhiyong Jiang  1 , Yan Zhu  1 , Xinguo Luo  1 , Fangjing Shi  1 , Shanshan Hu  1 , Xinfang Gao  1
Affiliations
Case Reports

Thalidomide-induced serious RR interval prolongation (longest interval >5.0 s) in multiple myeloma patient with rectal cancer: A case report

Li Huang et al. Open Med (Wars). .

Abstract

Primary secondary tumor increased recently with the use of immunomodulatory drugs in patients with multiple myeloma (MM). However, MM with prior diagnosis of primary secondary tumor is relatively rare. In this study, we reported an MM patient with prior diagnosis of rectal cancer. In brief, an 85-year-old man was first diagnosed with rectal cancer. Given the age, heart failure and small-cell hypochromic anemia (hemoglobin level: 54 g/L), rectal cancer resection was not advised and symptomatic treatments were performed (including sufficient iron supplementation). Eight months later, the patient was diagnosed with MM due to worsening anemia. Anemia and heart failure were corrected after three cycles of treatment with thalidomide, dexamethasone and capecitabine. Radical resection of rectal carcinoma (Hartmann) was finally performed due to acute abdominal distension. Meanwhile, RR interval prolongation (longest interval >5.0 s) and atrial fibrillation occurred in the fifth cycle treatment. One month after discontinuation of thalidomide, RR interval returned to normal range, while atrial fibrillation developed into persistent atrial fibrillation.

Keywords: RR interval prolongation; multiple myeloma; rectal cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Clinical and histopathological appearances. (a and b) HE staining results from thickened rectum showing adenocarcinoma. (c) Bone marrow cytology results showing increased plasmocyte. (d–g) Pathological and immunohistochemical results of bone marrow showing CD138 (+), CD38 (+), CD56 (partial +), Kappa (+), myelodysplastic activity and increased plasmocyte. (h) Excised rectal cancer.
Figure 2
Figure 2
ECG of patient during treatment. (a) Normal ECG before atrial fibrillation and RR interval prolongation; (b) the first holt result showing atrial fibrillation occurring during thalidomide treatment; (c) the first holt result showing serious RR interval prolongation (RR interval = 5.2 s) during thalidomide treatment; and (d) atrial fibrillation did not disappear after withdrawal.
See this image and copyright information in PMC

References

    1. Pratt G. Lenalidomide and second malignancies in myeloma patients. Lancet Oncol. 2014;15(3):253–4. - PubMed
    2. Pratt G. Lenalidomide and second malignancies in myeloma patients. Lancet Oncol. 2014;15(3):253–4. - PubMed
    1. Jones JR, Cairns DA, Gregory WM, Collett C, Pawlyn C, Sigsworth R, et al. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer J. 2016;6(12):e506. - PMC - PubMed
    2. Jones JR, Cairns DA, Gregory WM, Collett C, Pawlyn C, Sigsworth R. et al. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer J. 2016;6(12):e506. - PMC - PubMed
    1. Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol. 2013;31:2540–7. - PubMed
    2. Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE. et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol. 2013;31:2540–7. - PubMed
    1. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770–81. - PMC - PubMed
    2. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG. et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770–81. - PMC - PubMed
    1. Landgren O, Thomas A, Mailankody S. Myeloma and second primary cancers. N Engl J Med. 2011;365(23):2241–2. - PMC - PubMed
    2. Landgren O, Thomas A, Mailankody S. Myeloma and second primary cancers. N Engl J Med. 2011;365(23):2241–2. - PMC - PubMed

Publication types

LinkOut - more resources